Low-Income Women in Mexico Screened for Papillomavirus
By LabMedica International staff writers Posted on 25 Nov 2008 |
In a campaign to reduce cervical cancer in Mexico, all low-income women aged between 35 and 60 will be offered free testing for human papillomavirus (HPV).
The Mexican Public Health Agency (Secretaria de Salud; Cuauhtémoc Mexico City, Mexico) has launched the first phase of a program in which 200,000 women in the lowest-income 125 counties will be offered the papillomavirus test along with the traditional Papanicolaou (Pap) smear.
In early 2009, the pilot program will be expanded to include another 600,000 women in the 20 states with the highest death rate from cervical cancer. If the pilot program is successful, the remaining eight Mexican states will be included later in 2009.
The national screening program will use Qiagen's (Frankfurt, Germany) molecular digene test for HPV, the only such test approved by the U.S. Food and Drug Administration (FDA; Rockville, MD, USA). The digene HPV hc2 Test for the detection of human papillomavirus infections uses hybrid capture 2 technology. It detects 13 high-risk HPV and 5 low-risk HPV types and provides standardized, objective results.
Peer Schatz, CEO of Qiagen commented, ""Every year, more than 9,000 Mexican women are diagnosed with cervical cancer and nearly half of them die. Yet this is an entirely preventable disease."
Qiagen provides sample technologies used to isolate and process DNA, RNA, and proteins from biological samples such as blood or tissue. Assays make these isolated molecules visible to facilitate detection of disease and biologic research. The company provides products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing, and pharmaceutic process control.
Related Links:
Secretaria de Salud
Qiagen
U.S. Food and Drug Administration
The Mexican Public Health Agency (Secretaria de Salud; Cuauhtémoc Mexico City, Mexico) has launched the first phase of a program in which 200,000 women in the lowest-income 125 counties will be offered the papillomavirus test along with the traditional Papanicolaou (Pap) smear.
In early 2009, the pilot program will be expanded to include another 600,000 women in the 20 states with the highest death rate from cervical cancer. If the pilot program is successful, the remaining eight Mexican states will be included later in 2009.
The national screening program will use Qiagen's (Frankfurt, Germany) molecular digene test for HPV, the only such test approved by the U.S. Food and Drug Administration (FDA; Rockville, MD, USA). The digene HPV hc2 Test for the detection of human papillomavirus infections uses hybrid capture 2 technology. It detects 13 high-risk HPV and 5 low-risk HPV types and provides standardized, objective results.
Peer Schatz, CEO of Qiagen commented, ""Every year, more than 9,000 Mexican women are diagnosed with cervical cancer and nearly half of them die. Yet this is an entirely preventable disease."
Qiagen provides sample technologies used to isolate and process DNA, RNA, and proteins from biological samples such as blood or tissue. Assays make these isolated molecules visible to facilitate detection of disease and biologic research. The company provides products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing, and pharmaceutic process control.
Related Links:
Secretaria de Salud
Qiagen
U.S. Food and Drug Administration
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans